Posts Tagged ‘nasdaq’

« Older Entries
Newer Entries »

Nova Measuring Instruments Ltd. (NVMI) – Buzz Stock of the Day

Tuesday, August 3rd, 2010

Shares of metrology solutions provider, Nova Measuring Instruments Ltd. (Nasdaq: NVMI) surged as much as 27 percent from Monday’s closing price, in morning trading on Tuesday after the company announced record revenue in the second quarter, which topped analysts’ estimates.

Total revenues for the second quarter of 2010 were $19.4 million, an increase of 179% relative to the second quarter of 2009, and an increase of 22% relative to the first quarter of 2010.Gross margin for the second quarter of 2010 was 54%, compared with 41% in the second quarter of 2009, and 51% in the first quarter of 2010. Net income for the quarter was $4.7 million, or 18 cents per share.
[–quote–]
Analysts were looking for 12 cents a share profit on $16.9 million in revenue.

“Q2 was an excellent quarter, with record levels of revenues, profitability and operating cash flow” commentedGabi Seligsohn, President and CEO of Nova Measuring Instruments Ltd. in a statement. “These results demonstrate the success of our strategy which has focused on expanding our product offering, increasing our fab foot print and displacing traditional metrology techniques with our differentiated products.”

The company’s revised revenue guidance for 2010 is $78 million to$85 million. Based on this revenue guidance, the company is also guiding to net profitability of between 21 percent and 24 percent for the full-year.

Analysts on average were expecting $64 million, according to Thomson Reuters I/B/E/S.

Tags: , , , ,
Posted in Technology Stocks | No Comments »

FSI International, Inc. (FSII) – Buzz Stock of the Day

Monday, August 2nd, 2010

Shares of semiconductor equipment maker, FSI International, Inc. (Nasdaq: FSII) were up as much as 14 percent from Friday’s closing price, in morning trading on Monday. Last month, FSI International released strong third quarter results, driven by an 86 percent in revenue, over the previous year, topping the Street’s estimates of $28.1 million, and about in the middle of FSI International’s guidance range of $27 million to $29 million.

[–quote–]

Revenue for the quarter jumped to $28.7 million from $15.4 million in the prior-year quarter.Profit for the quarter was $5.9 million, or 18 cents a share,  compared to a loss of $2.8 million, or 9 cents a share, in a year earlier.

Sales for the first nine months of fiscal 2010 increased 71 percent to $62.2 million, compared to $36.3 million for the same period of fiscal 2009. The company’s net income for the first nine months of fiscal 2010 was $6.4 million, or $0.20 per share, as compared to a net loss of $17.6 million, or $0.57 per share for the first nine months of fiscal 2009.

FSI International said it expects orders in the fourth quarter to range between $27 million to $30 million and net income between $5 million and $6 million.

Tags: , , , , ,
Posted in Penny Stocks, Technology Stocks | No Comments »

DayStar Technologies, Inc. (DSTI) – Buzz Stock of the Day

Thursday, July 22nd, 2010

Shares of photovoltaic solar products products maker, DayStar Technologies, Inc. (Nasdaq: DSTI) rallied more than 75 percent from Wednesday’s closing price in morning trading on Thursday after the company announced that it is pursuing a strategy for offshore manufacturing of its CIGS thin-film deposition technology solar modules.

DayStar Technologies has “begun discussions with several potential partners,” which if consummated “could include joint ventures, licensing agreements, contract manufacturing agreements,” or even a reverse merger with or an acquisition of DayStar, according to CEO Magnus Ryde. “We are confident in our core proprietary CIGS technology and believe that completing a transaction with a strategic partner and manufacturing our CIGS modules offshore would provide the best opportunity to bring our product to market and to manufacture the product in the most cost effective manner,” said Ryde in a statement.
[–quote–]
DayStar was notified by its landlord, BMR-Gateway Boulevard LLC that the Company’s lease for the premises located at 7333-7373 Gateway Boulevard in Newark, California has been terminated.

For the first quarter, DayStar reported a net loss of $6.1 million or $1.61 per share, compared with a net loss of $7.7 million or $2.06 per share in the first quarter of 2009. The average shares outstanding and loss per share for the quarter ended March 31, 2010 and 2009 reflect the 1-for-9 reverse stock split implemented by DayStar on May 11, 2010. DayStar’s common stock began trading on the NASDAQ Capital Market on a split adjusted basis on March 12, 2010.

Solar stocks continue to have some buzz around them with stocks like STR Holdings (Nasdaq: STRI), Solarfun (Nasdaq: SOLF), Trina Solar (NYSE: TSL), JA Solar (Nasdaq: JASO), Renesola (NYSE: SOL), and GT Solar (Nasdaq: SOLR) all showing strong relative strength to the overall market the past year. Simmons & Co analyst Burt Chao recently told Reuters that “if we haven’t passed the bottom, we’re very, very close to it.” A look at the Solar Stocks Index shows that there is certainly no shortage of domestic components. However, data from the Solar Energy Industries Association suggests that solar power accounts for less than 1% of U.S. energy usage.

Tags: , , , , , , , , , , ,
Posted in Energy Stocks, Penny Stocks, Technology Stocks | 1 Comment »

Cypress Bioscience, Inc. (CYPB) – Buzz Stock of the Day

Monday, July 19th, 2010

Shares of drug maker Cypress Bioscience, Inc. (Nasdaq: CYPB) rallied as much as 41 percent from Friday’s closing price, in morning trading on Monday after hedge fund, Ramius offered to buy the company for about $154 million, or $4.00 a share in cash.

Ramius currently owns 9.9 percent of Cypress’ common stock. The offer of $4.00 per share is a 60 percent premium over Friday’s closing price of $2.50.

[–quote–]

In addition to the all-cash offer, Ramius also stated  that it would consider an acquisition structure that would allow management to continue the development of the recently acquired antipsychotic drug, BL-1020 if they are able to fund the required financing for the Phase IIb trial themselves or from a third party financing source.

In late June, Cypress Bioscience, Inc. entered  into an exclusive North American license for the development and commercialization of BioLineRx’s novel antipsychotic, BL-1020, a treatment for schizophrenia. Specific terms of the transaction were not disclosed, but the total upfront payment to BioLineRx was $30 million, with total potential clinical and regulatory milestones of up to $160 million through to approval in the United States, potential commercial milestones of $85 million, and a potential additional $90 million associated with approval for additional indications in the United States or for approval in other countries in North America. Cypress also agreed to fund all continuing development activities and pay BioLineRx a royalty based on applicable sales.

Ramius said poor decisions by Cypress management has damaged its stock price and that the company should hold off on making any further acquisitions or licensing deals. Shares of Cypress Bioscience are down about 73 percent over the past 12 months.

In a letter to Cypress management, Ramius said it is “ready, willing, and able to close this transaction expeditiously and expect the board to retain a reputable investment bank to immediately engage in discussions with us and any other potential acquirers to maximize value for all shareholders.”

Tags: , , , , ,
Posted in Health Care Stocks, Penny Stocks | No Comments »

Keryx Biopharmaceuticals, Inc. (KERX) – Hot Buzz Stock of the Day

Wednesday, July 14th, 2010

Shares of Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) climbed as much as 17 percent in morning trading Wednesday after the after the company announced its experimental childhood cancer drug, KRX-0401 (perifosine), had received Orphan Drug designation from U.S. Food and Drug Administration (FDA).

Commenting on receiving Orphan Drug designation, Ron Bentsur, Chief Executive Officer of Keryx stated, “We are currently exploring next steps for the development of perifosine in this indication which we hope, ultimately, could provide a new treatment option for children and infants suffering with neuroblastoma.

The FDA grants Orphan Drug status to new drugs that treat a rare disease afflicting fewer than 200,000 patients in the U.S. The benefits of Orphan Drug designation include seven-year marketing exclusivity if the drug is the first of its kind approved, tax credits for clinical research costs, the ability to apply for annual grant funding, clinical research trial design assistance and waiver of Prescription Drug User Fee Act (PDUFA) filing fees.

KRX-0401 is being developed for the treatment of neuroblastoma, a cancer of the nervous system affecting mostly children and infants. Although it is a rare form of cancer, neuroblastoma accounts for approximately 7 percent of all cancer deaths among children.

[–quote–]

Clinical Phase 1 data was presented last month in the pediatric solid tumor poster discussion session held at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Investigators from the Memorial Sloan-Kettering Cancer Center concluded that perifosine was demonstrated to be safe and well tolerated in children with advanced solid tumors and that perifosine may have antitumor clinical activity as a single agent in neuroblastoma.

Additionally, the Nationaly Cancer Institute recently published a preclinical study that found perifosine showed a statistically significant reduction in neuroblastoma cell survival, slowed or regressed tumor growth, and increased survival in mice bearing neuroblastoma tumors.

Tags: , , , , , , , ,
Posted in Health Care Stocks | No Comments »

« Older Entries
Newer Entries »